Support for Drug Development
Our Services
[DDS]
Cationic Peptide Conjugated with Folate Ligand (Fol-Dab8)Fol-Dab8 is innovative DDS technology that forms a complex when mixed with siRNA and delivers siRNA drugs to folate receptor-expressing cells (pancreatic cancer, brain tumors, breast cancer, etc.).
*This technology was co-developed with Professor Takeshi Wada of Tokyo University of Science and Associate Professor Keisuke Taniuchi of Kochi University.
[DDS]
New polymers for DDSWe are developing polymers to overcome the concerns of polyethylene glycol (PEG), a widely used polymer for DDS. Nanoparticle formulations using our polymer offer a new solution in DDS.
Heteroduplex Oligonucleotides (HDO)
Heteroduplex oligonucleotide (HDO) is the third platform technology for mRNA Therapeutics following short interfering RNA (siRNA) and single-stranded antisense oligonucleotide (ASO), which serves as a therapeutic agent for the modulation of specific genes at the post-transcriptional level. HDO is an artificial functioning nucleic acids composed of an antisense strand (gapmer, mixmer, PMO etc.) that binds to a transcript of a target gene and a carrier strand (RNA) that is complementary to the antisense strand. Since a ligand (receptor ligands, antibodies, lipids, etc.) is bound to the carrier strand, various ligands can be introduced without affecting the activity of the antisense strand enabling cell-specific delivery. HDO has high nuclear localization and low toxicity compared to ASO.
- Rena Therapeutics uses heteroduplex oligonucleotide (HDO) technology as its base technology. HDO technology was co-developed by Professor Takanori Yokota of Tokyo Medical and Dental University and Professor Satoshi Obika of Osaka University.
- Rena Therapeutics is a subsidiary of Nippon Shokubai.
Boranophosphate Oligonucleotides
We are developing chemical synthesis techniques and practical manufacturing methods for boranophosphate oligonucleotides, which have a new structure to replace conventional phosphorothioate oligonucleotides. Boranophosphate oligonucleotides are expected to reduce the toxicity of oligonucleotide drugs.
Human-type Glycan-Modified Glucocerebrosidase
This glycosylation enzyme has a uniform structure achieved by site-specific modification with human-type glycans. These changes are designed to transport the enzyme to specific cells and intracellular organelles, and give a stable pharmacological effect. This technology is the result of joint research with GlyTech, Inc.
Glycoprotein
with fully controlled
glycan structures
